卵巢癌合并直肠内瘘诊治中国专家共识(2025年版)

doi:10.11904/j.issn.1002-3070.2025.06.001

摘要/Abstract

摘要： 卵巢癌合并直肠内瘘在临床上较为少见。目前,对于如何平衡肠瘘治疗的紧迫性与卵巢癌手术时机及彻底性,尚无标准方案。本共识基于循证医学证据,结合国内外文献、相关指南及专家意见,提出系统化、可操作的诊疗策略。本共识强调,直肠内瘘的诊治应在肿瘤控制与瘘管安全处理之间取得平衡,提倡个体化治疗方案(包括保守治疗、营养支持、化疗、手术时机优化及内镜微创技术),并推荐多学科团队协作制定综合治疗计划,提高手术安全性并改善患者生活质量。

关键词: 卵巢癌, 直肠内瘘, 专家共识

Abstract: Ovarian cancer combined with internal rectal fistula is relatively rare in clinical practice.Currently,there is no standard protocol for balancing the urgency of intestinal fistula treatment with the timing and radicality of ovarian cancer surgery.This consensus is based on evidence-based medicine,combined with domestic and international literature,relevant guidelines,and expert opinions,to propose systematic and actionable diagnosis and treatment strategies.This consensus emphasizes that the diagnosis and treatment of rectal fistula should get a balance between tumor control and safe management of the fistula.It advocates individualized treatment plans(including conservative treatment,nutritional support,chemotherapy,optimized surgical timing,and endoscopic minimally invasive techniques),and recommends multidisciplinary team collaboration to develop comprehensive treatment plans,improve surgical safety,and enhance patients′ quality of life.

Key words: ovarian cancer, internal rectal fistula, expert consensus

中图分类号:

R737.3

中国抗癌协会中西整合卵巢癌专业委员会, 卵巢癌合并直肠内瘘诊治中国专家共识制定专家组. 卵巢癌合并直肠内瘘诊治中国专家共识(2025年版)[J]. 实用肿瘤学杂志, 2025, 39(6): 457-463.

Chinese Anti-Cancer Association Integrative Chinese and Western Medicine Ovarian Cancer Professional Committee, Expert Group for the Diagnosis and Treatment of Ovarian Cancer with Internal Rectal Fistula. Chinese expert consensus on the diagnosis and treatment of ovarian cancer with internal rectal fistula(2025 edition)[J]. Journal of Practical Oncology, 2025, 39(6): 457-463.

参考文献

1 Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
2 中国抗癌协会妇科肿瘤专业委员会.2022中国卵巢癌患者生存质量白皮书[R].北京:中国抗癌协会,2022.
3 Shannath M.WHO handbook for guideline development:2nd edition[M].World Health Organization,2014.
4 陈耀龙,杨克虎,王小钦,等.中国制订/修订临床诊疗指南的指导原则(2022版)[J].中华医学杂志,2022,102(10):7.
5 Guyatt G,Oxman AD,Akl EA,et al.GRADE guidelines:1.Introduction-GRADE evidence profiles and summary of findings tables[J].J Clin Epidemiol,2011,64(4):383-94.
6 张慧,章真,袁双虎.放射性直肠损伤的预防与治疗临床实践指南[J].中华肿瘤防治杂志,2023,30(5):245-259.
7 Burdan F,Sudol-szopinska I,Staroslawska E,et al.Magnetic resonance imaging and endorectal ultrasound for diagnosis of rectal lesions[J].Eur J Med Res,2015,20(1):4.
8 Tonolini M.Elucidating vaginal fistulas on CT and MRI[J].Insights Imaging,2019,10(1):123.
9 Gessler B,Eriksson O,Angenete E.Diagnosis,treatment,and consequences of anastomotic leakage in colorectal surgery[J].Int J Colorectal Dis,2017,32(4):549-556.
10 Marres CCM,Engelmann EWM,Buskens CJ,et al.The importance of rectal contrast in CT assessment to detect anastomotic leakage after colorectal surgery[J].Colorectal Dis,2021,23(9):2466-2471.
11 赵泽华,李铭,王伟忠.体部表面线圈磁共振成像对肛瘘的术前诊断价值[J].中国医学计算机成像杂志,2007,(6):440-443.
12 Arkenbosch JHC,Ruler O,Vries AC,et al.The role of MRI in perianal fistulizing disease:diagnostic imaging and classification systems to monitor disease activity[J].Abdom Radiol(NY),2025,50(2):589-597.
13 Zhao X,Yang P,Liu L,et al.Optimal debulking surgery in ovarian cancer patients:MRI may predict the necessity of rectosigmoid resection[J].Insights Imaging,2024,15(1):145.
14 朱维铭,贡钰霞.克罗恩病并发肠瘘综合治疗中的难点及对策[J].中国实用外科杂,2025,45(03):266-269+273.
15 中国抗癌协会妇科肿瘤专业委员会.妇科恶性肿瘤多学科诊疗中国专家共识(2022年版)[J].中国癌症杂志,2022,32(08):747-756.
16 Christensen MA,Gaitanidis A,Parks J,et al.Thirty-day outcomes in the operative management of intestinal-cutaneous fistulas:A NSQIP analysis[J].Am J Surg,2021,221(5):1050-1055.
17 Bonomo RA,Chow AW,Edwards MS,et al.2024 clinical practice guideline update by the infectious diseases society of America on complicated intra-abdominal infections:risk assessment,diagnostic imaging,and microbiological evaluation in adults,children,and pregnant people[J].Clin Infect Dis,2024,79(suppl 3):81-87.
18 Bhurwal A,Mutneja H,Tawadross A,et al.Gastrointestinal fistula endoscopic closure techniques[J].Ann Gastroenterol,2020,33(6):554-562.
19 Fukuya H,Iboshi Y,Wada M,et al.Gastric cancer presenting with ramucirumab-related gastrocolic fistula successfully managed by colonic stenting:a case report[J].Clin Endosc,2023,56(6):812-816.
20 Wang Q,Li J,Liu S,et al.Efficacy and safety of over-the-scope clips for colorectal leaks and fistulas:A pooled analysis[J].Minim Invasive Ther Allied Technol,2022,31(6):825-834.
21 Winder JS,Kulaylat AN,Schubart JR,et al.Management of non-acute gastrointestinal defects using the over-the-scope clips(OTSCs):a retrospective single-institution experience[J].Surg Endosc,2016,30(6):2251-2258.
22 Jung DH,Yun HR,Lee SJ,et al.Endoscopic vacuum therapy in patients with transmural defects of the upper gastrointestinal tract:a systematic review with meta-analysis[J].J Clin Med,2021,10(11):2346.
23 Kotzampassi K,Eleftheriadis E.Tissue sealants in endoscopic applications for anastomotic leakage during a 25-year period[J].Surgery,2015,157(1):79-86.
24 Maselli R,Palma R,Traina M,et al.Endoscopic suturing for GI applications:Initial results from a prospective multicenter European registry[J].Gastrointest Endosc,2022,96(5):780-786.
25 Struchkov VY,Berelavichus SV,Dvuhzhilov MV,et al.Complex treatment of multiple high-output enterocutaneous fistulas(gastric,jejunum,transversum)after bariatric surgery[J].J Surg Case Rep,2023,2023(3):rjad096.
26 Pironi L,Cuerda C,Jeppesen PB,et al.ESPEN guideline on chronic intestinal failure in adults-Update 2023[J].Clin Nutr,2023,42(10):1940-2021.
27 Gao X,Liu Y,Zhang L,et al.Effect of early vs late supplemental parenteral nutrition in patients undergoing abdominal surgery:a randomized clinical trial[J].JAMA Surg,2022,157(5):384-393.
28 Bacalbasa N,Balescu I,Diaconu C,et al.Right upper abdominal resections in advanced stage ovarian cancer[J].In Vivo,2020,34(3):1487-1492.
29 Tozzi R,Casarin J,Garruto-Campanile R,et al.Morbidity and reversal rate of ileostomy after bowel resection during Visceral-Peritoneal Debulking(VPD)in patients with stage IIIC-IV ovarian cancer[J].Gynecol Oncol,2018,148(1):74-78.
30 Scarborough JE,Schumacher J,Kent KC,et al.Associations of specific postoperative complications with outcomes after elective colon resection:a procedure-targeted approach toward surgical quality improvement[J].JAMA Surg,2017,152(2):e164681.
31 Wang H,Li X,Jiang Y,et al.Clinical analysis of different intestinal reconstruction methods after primary cytoreductive surgery combined with rectal resection for advanced ovarian cancer[J].Front Oncol,2025,15:1500042.
32 Smith JD,Butte JM,Weiser MR,et al.Anastomotic leak following low anterior resection in stage IV rectal cancer is associated with poor survival[J].Ann Surg Oncol,2013,20(8):2641-2646.
33 Arron MNN,Greijdanus NG,Bastiaans S,et al.Long-term oncological outcomes after colorectal anastomotic leakage:a retrospective dutch population-based study[J].Ann Surg,2022,276(5):882-889.
34 Sciuto A,Merola G,De Palma GD,et al.Predictive factors for anastomotic leakage after laparoscopic colorectal surgery[J].World J Gastroenterol,2018,24(21):2247-2260.
35 Restaino S,Schierano S,Arcieri M,et al.Surgical management of anastomotic leakage related to ovarian cancer surgery:a narrative review[J].Front Surg,2024,11:1434730.
36 Ghimire P.Management of enterocutaneous fistula:a review[J].JNMA J Nepal Med Assoc,2022,15:60(245):93-100.
37 陈军,陈康,王康磊,等.合并肠瘘肿瘤病人综合治疗策略探讨[J].肠外与肠内营养,2021,28(06):342-346.
38 Cazzaniga ME,Cordani N,Capici S,et al.Metronomic chemotherapy[J].Cancers(Basel),2021,13(9):2236.
39 梁语丝,谭永刚,邹华伟.低剂量化疗作用机制的研究进展[J].实用肿瘤学杂志,2017,31(6):538-542.
40 Katsumata N,Yasuda M,Isonishi S,et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian,fallopian tube,or primary peritoneal cancer(JGOG 3016):a randomised,controlled,open-label trial[J].Lancet Oncol,2013,14(10):1020-1026.
41 Pignata S,Scambia G,Katsaros D,et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer(MITO-7):a randomised,multicentre,open-label,phase 3 trial[J].Lancet Oncol,2014,15(4):396-405.
42 Blagden SP,Cook AD,Poole C,et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer(ICON8):quality-of-life results of a phase 3,randomised,controlled trial[J].Lancet Oncol,2020,21(7):969-977.
43 Liu Y,Zhang T,Wu Q,et al.Relationship between initiation time of adjuvant chemotherapy and survival in ovarian cancer patients:a dose-response meta-analysis of cohort studies[J].Sci Rep,2017,7(1):9461.
44 Mahner S,Eulenburg C,Staehle A,et al.Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer:analysis of prospective randomised phase III trials[J].Eur J Cancer,2013,49(1):142-149.
45 Hofstetter G,Concin N,Braicu I,et al.The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma-analysis of patient data in the prospective OVCAD study[J].Gynecol Oncol,2013,131(1):15-20.
46 Ni S,He J,Ouyang L.The value of transitory protective stomas during primary debulking surgery for advanced epithelial ovarian cancer:a retrospective cohort study[J].Int J Surg,2024,110(11):6922-6932.
47 Hapani S,Chu D,Wu S.Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab:a meta-analysis[J].Lancet Oncol,2009,10(6):559-568.
48 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)结直肠癌诊疗指南[M].2024版.北京:人民卫生出版社,2024.

[1]	中国抗癌协会中西整合卵巢癌专业委员会, 妇科手术肠道准备中国专家共识制定专家组. 妇科手术肠道准备中国专家共识(2025年版)[J]. 实用肿瘤学杂志, 2025, 39(5): 363-371.
[2]	吴小帆, 李琳. 卵巢癌中紫杉醇耐药性研究进展[J]. 实用肿瘤学杂志, 2025, 39(4): 343-347.
[3]	苏少飞, 张恩婕, 刘建辉, 高燕. 基于孟德尔随机化探究20种代谢产物与卵巢癌发病风险的因果关联[J]. 实用肿瘤学杂志, 2025, 39(3): 191-200.
[4]	寇帅, 王榆平, 孙小霞, 任娟娟. 基于年龄-时期-队列模型的1992—2021年中国卵巢癌发病和死亡分析[J]. 实用肿瘤学杂志, 2025, 39(1): 7-12.
[5]	孙莉君, 董大伟. 基于铂类耐药相关基因的卵巢癌分型和预后研究[J]. 实用肿瘤学杂志, 2024, 38(3): 184-191.
[6]	高燕, 韩晓阳, 程瑾, 侯丽莎, 岳文涛. 单细胞转录组数据揭示PHLDA1是卵巢癌T细胞耗竭的关键分子[J]. 实用肿瘤学杂志, 2024, 38(2): 79-87.
[7]	高燕, 姚盟成, 李哲丰, 韩晓阳, 岳文涛. 单细胞测序数据揭示DMKN在卵巢癌中的诊断及预测价值[J]. 实用肿瘤学杂志, 2023, 37(6): 478-484.
[8]	樊婷婷, 丁丹妮, 赵子雪, 于洋, 韩凤娟. 脂肪酸代谢与卵巢癌[J]. 实用肿瘤学杂志, 2023, 37(5): 429-433.
[9]	孙阜圣, 徐冶, 张永健, 娄阁. 卵巢癌类器官模型的研究进展和治疗新策略[J]. 实用肿瘤学杂志, 2022, 36(4): 346-350.
[10]	尹翼, 欧朝阳, 何爱琴. GAB2在卵巢癌组织中的表达及其与预后的相关性[J]. 实用肿瘤学杂志, 2022, 36(2): 150-155.
[11]	董丽娜, 梁田, 张献, 张广美. 卵巢癌对富脂大网膜的器官趋向性转移的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 54-58.
[12]	张文文,姜亮亮(综述),王晶(审校). CAR-T疗法在卵巢癌中的应用前景[J]. 实用肿瘤学杂志, 2021, 35(1): 59-63.
[13]	侯建英, 朱巍. 免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 266-270.
[14]	梁永琴, 赵宏伟. 抗血管生成药物在铂耐药卵巢癌中的应用进展[J]. 实用肿瘤学杂志, 2020, 34(1): 60-63.
[15]	黄梨, 龙佑梅, 付义霞, 夏良斌. 紫檀芪对卵巢癌SKOV3细胞凋亡和糖酵解的影响及机制研究[J]. 实用肿瘤学杂志, 2019, 33(6): 502-507.